Biocon Receives Health Canada Approval of Bosaya™ and Vevzuo™ (Denosumab biosimilars to Prolia® and Xgeva®) for bone health.
BENGALURU, India & BRIDGEWATER, N.J.-- (BUSINESS WIRE)--Apr 7, 2026-- ...
Pharmaceutical Technology on MSN
Health Canada approves Biocon’s two denosumab biosimilars
Denosumab therapies are used to increase bone mass and treat osteoporosis, as well as address bone complications in cancer.
Profit rises 71% YoY to Rs 144 crore Biocon Biologics share which constitutes 45% of revenues reported 29% YoY growth to Rs ...
Biocon Biologics has been positioning itself to become a global player in biosimilar drugs. Viatris, a longtime partner to Biocon, is charting a course for its future that does not include biosimilars ...
Bengaluru/Toronto: Biocon is stepping up its global biosimilars play with fresh approvals in Canada, targeting large patient ...
At around 10:42 a.m., Biocon shares were up 1.51 per cent, or Rs 3.6, at Rs 242.05 apiece on BSE. The market capitalisation ...
Appointment expands HR leadership across regions as Biocon scales global operations and talent strategy. Biocon has appointed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results